Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TNF-α blockade mitigates immune checkpoint–related nephritis in a humanized mouse model
Victor D. Cuenca Narvaez, Coraima Nava Chavez, Omar Al Refai, Johanna E.J. Jacobs, Luis E. Gutierrez, Song Zhang, Xiaoyan Li, Jacob B. Hirdler, Michael F. Romero, Joerg Herrmann, Xiaogang Li, Haidong Dong, Alfonso Eirin, Sandra M. Herrmann
Victor D. Cuenca Narvaez, Coraima Nava Chavez, Omar Al Refai, Johanna E.J. Jacobs, Luis E. Gutierrez, Song Zhang, Xiaoyan Li, Jacob B. Hirdler, Michael F. Romero, Joerg Herrmann, Xiaogang Li, Haidong Dong, Alfonso Eirin, Sandra M. Herrmann
View: Text | PDF
Research Article Immunology Inflammation Nephrology

TNF-α blockade mitigates immune checkpoint–related nephritis in a humanized mouse model

  • Text
  • PDF
Abstract

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), with acute interstitial nephritis (ICI-AIN) being the most common irAE. While the exact mechanism remains unclear, upregulation of IFN-γ and TNF-α pathways has been implicated. This study used a humanized chimeric PD-1/PD-L1 mouse model to assess renal effects of ICIs, alone or combined with proinflammatory cytokines, and to test if selective TNF-α blockade could prevent ICI-AIN. Mice were randomly divided into 4 experimental groups: Control, ICI-Only, ICI-Cytokines (ICI-Cyt), and ICI-Block (ICI-TNF-α blockade). Renal function and cytokine profiles were assessed, while kidney tissue was analyzed using microscopy and single-cell RNA-seq. Histology revealed increased renal infiltration of CD4+/CD8+ T cells in ICI-treated groups and decreased TNF-α expression following TNF-α blockade. Additionally, kidney tissue ELISA demonstrated reduced IFN-γ levels following TNF-α blockade. Plasma IL-6, MCP-1, and TNF-α were lower in ICI-Block mice. Single-cell RNA-seq revealed shifts in immune cell populations and genes of interest including Bcl2a1, Icos, Il18r1, Ccr2, and Jaml. This humanized model replicates ICI-AIN key features, revealing a synergistic role of ICIs and proinflammatory cytokines. TNF-α blockade demonstrated protective effects, supporting its potential role in mitigating the risk of ICI-AIN.

Authors

Victor D. Cuenca Narvaez, Coraima Nava Chavez, Omar Al Refai, Johanna E.J. Jacobs, Luis E. Gutierrez, Song Zhang, Xiaoyan Li, Jacob B. Hirdler, Michael F. Romero, Joerg Herrmann, Xiaogang Li, Haidong Dong, Alfonso Eirin, Sandra M. Herrmann

×

Figure 1

CD4+ and CD8+ tubular T cell number by immune checkpoint inhibitor treatment regimen.

Options: View larger image (or click on image) Download as PowerPoint
CD4+ and CD8+ tubular T cell number by immune checkpoint inhibitor treat...
(A) Representative images of H&E staining (top row) and CD4+/CD8+ immunofluorescence (IF) staining (middle and bottom rows, respectively). White square highlight interstitial areas of interest in both H&E and IF images. (B and C) Quantification of tubular CD4+/CD8+ cells per medium power field (MPF) across groups. P values derived from Kruskal-Wallis followed by Dunn’s multiple-comparison test for post hoc analysis. Experiment was done once. *P < 0.05 for group ICI-Only (median: 5.96 CD4+ cells, 5.85 CD8+ cells) versus Control group (median: 1.9 CD4+ cells, 2.25 CD8+ cells) in post hoc test adjusted for multiple comparisons. †P < 0.05 for group ICI-Cyt (median: 8.2 CD4+ cells, 7.05 CD8+ cells) versus Control group (median: 1.9 CD4+ cells, 2.25 CD8+ cells) in post hoc test adjusted for multiple comparisons. Scale bars: 50 μm and 15 μm as indicated.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts